

# CITATION REPORT

List of articles citing

**Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders**

**DOI: 10.1016/j.eururo.2004.12.005**

**European Urology, 2005, 47, 518-22; discussion 522-3.**

**Source:** <https://exaly.com/paper-pdf/38255960/citation-report.pdf>

**Version:** 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
71	Current World Literature. <i>Current Opinion in Urology</i> , <b>2005</b> , 15, 410-415	2.8	
70	Vardenafil in the treatment of erectile dysfunction: a review of clinical data. <i>Aging Health</i> , <b>2005</b> , 1, 367-377		1
69	Psychosocial evaluation and combination treatment of men with erectile dysfunction. <i>Urologic Clinics of North America</i> , <b>2005</b> , 32, 431-45, vi	2.9	30
68	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. <i>Drugs</i> , <b>2005</b> , 65, 1621-50	12.1	133
67	Psychological, Social, and Behavioural Benefits for Men Following Effective Erectile Dysfunction (ED) Treatment: Men Who Enjoy Better Sex Experience Improved Psychological Well-Being. <i>European Urology Supplements</i> , <b>2006</b> , 5, 773-778	0.9	6
66	Partner Satisfaction and Successful Treatment Outcomes for Men with Erectile Dysfunction (ED). <i>European Urology Supplements</i> , <b>2006</b> , 5, 779-785	0.9	8
65	Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance?. <i>The Journal of Men's Health &amp; Gender: the Official Journal of the International Society for Men's Health &amp; Gender</i> , <b>2006</b> , 3, 342-349		5
64	Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. <i>Urology</i> , <b>2006</b> , 68, 397-401	1.6	12
63	A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction. <i>Urology</i> , <b>2006</b> , 68, 38-46	1.6	17
62	Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression. <i>CNS Spectrums</i> , <b>2006</b> , 11, 31-7	1.8	14
61	The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. <i>Diabetic Medicine</i> , <b>2006</b> , 23, 873-8	3.5	48
60	Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. <i>International Journal of Impotence Research</i> , <b>2006</b> , 18, 550-8	2.3	17
59	Salvaging the oral treatment failure patient. <i>Current Sexual Health Reports</i> , <b>2006</b> , 3, 20-24	1.2	1
58	Educating physicians to treat erectile dysfunction patients: development and evaluation of a course on communication and management strategies. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 47-55	1.1	34
57	Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate. <i>Journal of Sexual Medicine</i> , <b>2006</b> , 3, 668-675	1.1	14
56	Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. <i>European Urology</i> , <b>2006</b> , 50, 134-40	10.2	54
55	Treatment strategy for "non-responders" to tadalafil and vardenafil: a real-life study. <i>European Urology</i> , <b>2006</b> , 50, 126-32; discussion 132-3	10.2	42

54	Counseling patients about sexual issues. <i>Pharmacotherapy</i> , <b>2006</b> , 26, 1608-15	5.8	6
53	Sildenafil in the treatment of erectile dysfunction. <i>Aging Health</i> , <b>2007</b> , 3, 295-303		2
52	Testosterone and Erection: Practical Management for the Patient with Erectile Dysfunction. <i>European Urology Supplements</i> , <b>2007</b> , 6, 868-873	0.9	8
51	Treatment options for erectile dysfunction. <i>Endocrinology and Metabolism Clinics of North America</i> , <b>2007</b> , 36, 465-79	5.5	32
50	Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. <i>International Journal of Impotence Research</i> , <b>2007</b> , 19, 281-95	2.3	33
49	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. <i>Aging Health</i> , <b>2007</b> , 3, 527-542		1
48	Phosphodiesterase inhibitors in the treatment of erectile dysfunction in spinal cord-injured men. <i>Spinal Cord</i> , <b>2007</b> , 45, 169-73	2.7	54
47	How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. <i>International Journal of Urology</i> , <b>2007</b> , 14, 339-42; discussion 343	2.3	23
46	Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. <i>International Journal of Clinical Practice</i> , <b>2007</b> , 61, 1850-62	2.9	27
45	Phosphodiesterase type 5 inhibitors: the day after. <i>European Urology</i> , <b>2007</b> , 51, 75-88; discussion 89	10.2	73
44	Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). <i>European Urology</i> , <b>2007</b> , 51, 541-50; discussion 550	10.2	44
43	A rational combination pharmacotherapy in men with erectile dysfunction who initially failed to oral sildenafil citrate alone: a pilot study. <i>Journal of Sexual Medicine</i> , <b>2007</b> , 4, 1136-41	1.1	13
42	Can an educational program optimize PDE5i therapy? A study of Canadian primary care practices. <i>Journal of Sexual Medicine</i> , <b>2007</b> , 4, 1404-13	1.1	13
41	JSSM Guidelines for erectile dysfunction. <i>International Journal of Urology</i> , <b>2008</b> , 15, 564-76	2.3	8
40	Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. <i>BJU International</i> , <b>2008</b> , 102, 1645-50	5.6	19
39	Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. <i>European Urology</i> , <b>2008</b> , 53, 564-70	10.2	70
38	Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 469-75	1.1	33
37	The effect of physician and patient education when combined with vardenafil treatment in Canadian males with erectile dysfunction: an open-label, factorial-designed, cluster-randomized clinical trial. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 705-15	1.1	3

36	Does educational status affect a patient's behavior toward erectile dysfunction?. <i>Journal of Sexual Medicine</i> , <b>2008</b> , 5, 1941-8	1.1	15
35	Salvage therapy trial for erectile dysfunction using phosphodiesterase type 5 inhibitors and vitamin E: preliminary report. <i>Aging Male</i> , <b>2008</b> , 11, 167-70	2.1	9
34	Nocturnal erections, differential diagnosis of impotence, and diabetes. I Karacan, FB Scott, PJ Salis, SL Attia, JC Ware, A Altinel, and RL Williams. <i>Journal of Sexual Medicine</i> , <b>2009</b> , 6, 318-23	1.1	4
33	Efficacy and safety of tadalafil taken as needed for the treatment of erectile dysfunction in Asian men: results of an integrated analysis. <i>Asian Journal of Andrology</i> , <b>2009</b> , 11, 423-33	2.8	7
32	Toward a new EPOCHS optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1214-30	2.9	17
31	Endothelial antioxidant administration ameliorates the erectile response to PDE5 regardless of the extension of the atherosclerotic process. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 1247-53	1.1	23
30	What's new in sex therapy (CME). <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 5-13; quiz 14-5	1.1	35
29	Penile rehabilitation protocol after robot-assisted radical prostatectomy: assessment of compliance with phosphodiesterase type 5 inhibitor therapy and effect on early potency. <i>BJU International</i> , <b>2010</b> , 105, 382-8	5.6	24
28	Estudio comparativo de las características de los pacientes con disfunción eréctil y su manejo inicial en diferentes centros uro-andrológicos españoles. <i>Revista Internacional De Andrología</i> , <b>2011</b> , 9, 145-153	0.6	0
27	Optimizing treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction: opening windows to enhanced sexual function and overall health. <i>Journal of the American Academy of Nurse Practitioners</i> , <b>2011</b> , 23, 320-30		6
26	Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. <i>International Journal of Hypertension</i> , <b>2012</b> , 2012, 627278	2.4	44
25	Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. <i>Journal of Sexual Medicine</i> , <b>2012</b> , 9, 2361-9	1.1	77
24	A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 707-17	2.5	10
23	A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 695-706	2.5	10
22	Dépistage et prise en charge de la dysfonction érectile des patients diabétiques : une nécessité pour tout praticien. <i>Revue de littérature. Sexologies</i> , <b>2013</b> , 22, 3-9	0.5	2
21	Screening and managing erectile dysfunction in diabetic patients (review). <i>Sexologies</i> , <b>2013</b> , 22, e1-e8	0.5	4
20	Arterial erectile dysfunction: different severities of endothelial apoptosis between diabetic patients "responders" and "non responders" to sildenafil. <i>European Journal of Internal Medicine</i> , <b>2013</b> , 24, 234-40	3.9	19
19	Erectile Dysfunction: The Medical Treatment. <i>European Urology Supplements</i> , <b>2013</b> , 12, 13-17	0.9	3

18	Treatment Strategy for Non-Responders to PDE5 Inhibitors. <i>World Journal of Men's Health</i> , <b>2013</b> , 31, 31-5	6.8	24
17	Korean Society for Sexual Medicine and Andrology (KSSMA) Guideline on Erectile Dysfunction. <i>World Journal of Men's Health</i> , <b>2013</b> , 31, 83-102	6.8	22
16	Nonresponse to PDE5 inhibitors in erectile dysfunction. Part 2. <i>Human Andrology</i> , <b>2014</b> , 4, 45-53	1	
15	Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study. <i>International Journal of Clinical Practice</i> , <b>2014</b> , 68, 1087-99	2.9	15
14	Association of psychological factors, patients knowledge, and management among patients with erectile dysfunction. <i>Patient Preference and Adherence</i> , <b>2016</b> , 10, 807-23	2.4	9
13	Non-invasive Management Options for Erectile Dysfunction When a Phosphodiesterase Type 5 Inhibitor Fails. <i>Drugs and Aging</i> , <b>2018</b> , 35, 175-187	4.7	12
12	Pharmacosexology: Psychiatric Side Effects of Drugs for the Treatment of Sexual Dysfunction. <i>Trends in Andrology and Sexual Medicine</i> , <b>2018</b> , 225-249	0.5	
11	Assessment of Combination Therapies vs Monotherapy for Erectile Dysfunction: A Systematic Review and Meta-analysis. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2036337	10.4	4
10	The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 735708	5.6	3
9	Psychosocial Aspects Related to Erectile Dysfunction. <b>2006</b> , 105-122		1
8	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. <i>Clinical Interventions in Aging</i> , <b>2006</b> , 1, 403-14	4	36
7	NHG-Standaard Erectiele disfunctie. <b>2009</b> , 1291-1313		
6	NHG-Standaard Erectiele disfunctie. <b>2011</b> , 1495-1517		
5	Erectile Dysfunction. <b>2015</b> , 65-116		
4	Treating Erectile Dysfunctions. <b>2017</b> , 201-225		
3	Erectile dysfunction: drug treatment. <i>Revista Da Associação Médica Brasileira</i> , <b>2019</b> , 65, 1133-1142	1.4	1
2	Evaluation and Management of Erectile Dysfunction. <b>2021</b> , 93-126		
1	Medication strategies regarding erectile dysfunction and associated treatment drop out and compliance TA retrospective study of 516 patients. <b>2022</b> ,		0

